Evolutionary rescue of phosphomannomutase deficiency in yeast models of human disease

  1. Ryan C Vignogna
  2. Mariateresa Allocca
  3. Maria Monticelli
  4. Joy W Norris
  5. Richard Steet
  6. Ethan O Perlstein
  7. Giuseppina Andreotti  Is a corresponding author
  8. Gregory I Lang  Is a corresponding author
  1. Lehigh University, United States
  2. National Research Council, Italy
  3. Greenwood Genetic Center, United States
  4. Perlara PBC, United States

Abstract

The most common cause of human congenital disorders of glycosylation (CDG) are mutations in the phosphomannomutase gene PMM2, which affect protein N-linked glycosylation. The yeast gene SEC53 encodes a homolog of human PMM2. We evolved 384 populations of yeast harboring one of two human-disease-associated alleles, sec53-V238M and sec53-F126L, or wild-type SEC53. We find that after 1,000 generations, most populations compensate for the slow-growth phenotype associated with the sec53 human-disease-associated alleles. Through whole-genome sequencing we identify compensatory mutations, including known SEC53 genetic interactors. We observe an enrichment of compensatory mutations in other genes whose human homologs are associated with Type 1 CDG, including PGM1, which encodes the minor isoform of phosphoglucomutase in yeast. By genetic reconstruction, we show that evolved pgm1 mutations are dominant and allele-specific genetic interactors that restore both protein glycosylation and growth of yeast harboring the sec53-V238M allele. Finally, we characterize the enzymatic activity of purified Pgm1 mutant proteins. We find that reduction, but not elimination, of Pgm1 activity best compensates for the deleterious phenotypes associated with the sec53-V238M allele. Broadly, our results demonstrate the power of experimental evolution as a tool for identifying genes and pathways that compensate for human-disease associated alleles.

Data availability

The short-read sequencing data reported in this study have been deposited to the NCBI BioProject database, accession number PRJNA784975.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Ryan C Vignogna

    Department of Biological Sciences, Lehigh University, Bethlehem, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5943-6464
  2. Mariateresa Allocca

    Institute of Biomolecular Chemistry, National Research Council, Pozzuoli, Italy
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3693-2515
  3. Maria Monticelli

    Institute of Biomolecular Chemistry, National Research Council, Pozzuoli, Italy
    Competing interests
    No competing interests declared.
  4. Joy W Norris

    Research Division, Greenwood Genetic Center, Greenwood, United States
    Competing interests
    No competing interests declared.
  5. Richard Steet

    Research Division, Greenwood Genetic Center, Greenwood, United States
    Competing interests
    No competing interests declared.
  6. Ethan O Perlstein

    Perlara PBC, Berkeley, United States
    Competing interests
    Ethan O Perlstein, is CEO of Maggie's Pearl, LLC and CEO of Perlara PBC. He holds an ownership stake in both companies..
  7. Giuseppina Andreotti

    Institute of Biomolecular Chemistry, National Research Council, Pozzuoli, Italy
    For correspondence
    gandreotti@icb.cnr.it
    Competing interests
    No competing interests declared.
  8. Gregory I Lang

    Department of Biological Sciences, Lehigh University, Bethlehem, United States
    For correspondence
    glang@lehigh.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7931-0428

Funding

National Institutes of Health (R01GM127420)

  • Gregory I Lang

National Institutes of Health (P20GM139769)

  • Richard Steet

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Vignogna et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,290
    views
  • 167
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ryan C Vignogna
  2. Mariateresa Allocca
  3. Maria Monticelli
  4. Joy W Norris
  5. Richard Steet
  6. Ethan O Perlstein
  7. Giuseppina Andreotti
  8. Gregory I Lang
(2022)
Evolutionary rescue of phosphomannomutase deficiency in yeast models of human disease
eLife 11:e79346.
https://doi.org/10.7554/eLife.79346

Share this article

https://doi.org/10.7554/eLife.79346

Further reading

    1. Ecology
    2. Evolutionary Biology
    Rebecca D Tarvin, Jeffrey L Coleman ... Richard W Fitch
    Research Article

    Understanding the origins of novel, complex phenotypes is a major goal in evolutionary biology. Poison frogs of the family Dendrobatidae have evolved the novel ability to acquire alkaloids from their diet for chemical defense at least three times. However, taxon sampling for alkaloids has been biased towards colorful species, without similar attention paid to inconspicuous ones that are often assumed to be undefended. As a result, our understanding of how chemical defense evolved in this group is incomplete. Here, we provide new data showing that, in contrast to previous studies, species from each undefended poison frog clade have measurable yet low amounts of alkaloids. We confirm that undefended dendrobatids regularly consume mites and ants, which are known sources of alkaloids. Thus, our data suggest that diet is insufficient to explain the defended phenotype. Our data support the existence of a phenotypic intermediate between toxin consumption and sequestration — passive accumulation — that differs from sequestration in that it involves no derived forms of transport and storage mechanisms yet results in low levels of toxin accumulation. We discuss the concept of passive accumulation and its potential role in the origin of chemical defenses in poison frogs and other toxin-sequestering organisms. In light of ideas from pharmacokinetics, we incorporate new and old data from poison frogs into an evolutionary model that could help explain the origins of acquired chemical defenses in animals and provide insight into the molecular processes that govern the fate of ingested toxins.

    1. Computational and Systems Biology
    2. Evolutionary Biology
    Pierre Barrat-Charlaix, Richard A Neher
    Research Article

    As pathogens spread in a population of hosts, immunity is built up, and the pool of susceptible individuals are depleted. This generates selective pressure, to which many human RNA viruses, such as influenza virus or SARS-CoV-2, respond with rapid antigenic evolution and frequent emergence of immune evasive variants. However, the host’s immune systems adapt, and older immune responses wane, such that escape variants only enjoy a growth advantage for a limited time. If variant growth dynamics and reshaping of host-immunity operate on comparable time scales, viral adaptation is determined by eco-evolutionary interactions that are not captured by models of rapid evolution in a fixed environment. Here, we use a Susceptible/Infected model to describe the interaction between an evolving viral population in a dynamic but immunologically diverse host population. We show that depending on strain cross-immunity, heterogeneity of the host population, and durability of immune responses, escape variants initially grow exponentially, but lose their growth advantage before reaching high frequencies. Their subsequent dynamics follows an anomalous random walk determined by future escape variants and results in variant trajectories that are unpredictable. This model can explain the apparent contradiction between the clearly adaptive nature of antigenic evolution and the quasi-neutral dynamics of high-frequency variants observed for influenza viruses.